Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease

INTRODUCTION: The benefit of adding an immunomodulator to vedolizumab and ustekinumab remains unclear and may compromise the safety of these biologics. We evaluated the prevalence and predictors of immunomodulator use with vedolizumab or ustekinumab in patients with inflammatory bowel disease in a l...

Descripción completa

Detalles Bibliográficos
Autores principales: Lutz, Megan, Caldera, Freddy, Schroeder, Katie, Gazis, Derek, Crawford, Julie M., Long, Millie D., Barnes, Edward L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684180/
https://www.ncbi.nlm.nih.gov/pubmed/37450671
http://dx.doi.org/10.14309/ctg.0000000000000620

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684180/
https://www.ncbi.nlm.nih.gov/pubmed/37450671
http://dx.doi.org/10.14309/ctg.0000000000000620

Ejemplares similares